A novel scoring system for pivotal autophagy-related genes predicts outcomes after chemotherapy in advanced ovarian cancer patients
Cancer Epidemiology, Biomarkers & Prevention Nov 12, 2019
Niu Y, Sun W, Chen K, et al. - In patients with stage III/IV ovarian cancer who received chemotherapy, researchers established a scoring system based on expression profiles of pivotal autophagy-related (ATG) genes. They used data of ovarian serous cystadenocarcinoma in The Cancer Genome Atlas (TCGA-OV) as the training dataset. To develop the ATG score, 43 ATG genes were chosen. Patients with lower ATG scores had better overall survival (OS) and recurrence-free survival in TCGA-OV. The rate of recurrence was 47.2% in the low-score group and 68.3% in the high-score group after complete or partial remission to primary therapy. In the two validation datasets, such findings were verified. A novel scoring system based on pivotal ATG genes was established, which precisely anticipates the outcomes of patients with advanced ovarian cancer after chemotherapy.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries